Thu, February 23, 2023
Wed, February 22, 2023
Tue, February 21, 2023
Mon, February 20, 2023
Fri, February 17, 2023

Paul Choi Upgraded (VIR) to Strong Buy and Increased Target to $53 on, Feb 21st, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-53-on-feb-21st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Paul Choi of Goldman Sachs, Upgraded "Vir Biotechnology, Inc." (VIR) to Strong Buy and Increased Target from $41 to $53 on, Feb 21st, 2023.

Paul has made no other calls on VIR in the last 4 months.



There are 4 other peers that have a rating on VIR. Out of the 4 peers that are also analyzing VIR, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Upgraded from Sell to Hold and Increased Target to $30 on, Friday, January 27th, 2023


These are the ratings of the 3 analyists that currently disagree with Paul


  • Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $43 on, Friday, January 27th, 2023
  • Andrew Galler of "Morgan Stanley" Maintained at Sell with Increased Target to $18 on, Friday, November 4th, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $32 on, Friday, November 4th, 2022

Publication Contributing Sources